Linked Life Data

21948172

Source:http://linkedlifedata.com/resource/pubmed/id/21948172

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-11-3
pubmed:abstractText
Echinocandins are parenteral antifungals with a unique site of action targeting the cell wall synthesis. There are three molecules available, anidulafungin, caspofungin, and micafungin, which have fungicidal and fungistatic activity against Candida and Aspergillus, respectively, and an excellent safety profile. There is consistent proof of clinical activity against Aspergillus for caspofungin, while less is known for micafungin and even lees for anidulafungin. Micafungin and caspofungin have been successfully used in targeted treatment of aspergillosis, prophylaxis, and empirical therapy, both as monotherapy and in combination with other antifungals. Caspofungin is approved for empirical therapy of febrile neutropenia and salvage treatment of invasive aspergillosis, whereas micafungin is only licensed for antifungal prophylaxis in stem cell transplantation.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Dec
pubmed:issn
1534-3146
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
517-27
pubmed:year
2011
pubmed:articleTitle
Current role of echinocandins in the management of invasive aspergillosis.
pubmed:affiliation
Division of Infectious Diseases, University of Genova, San Martino University Hospital, L.go R. Benzi, 10 16132, Genoa, Italy.
pubmed:publicationType
Journal Article